PUER is a precision medicine company that integrates genomics, proteomics, and metabolomics to map an individual's biology at the molecular level, enabling early disease detection and personalized health interventions. The company's platform, developed through over a decade of research and validated in clinical trials, helps physicians identify health risks and optimize wellness and longevity trajectories.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional medicine relies on population-level statistics, meaning treatments often benefit only a small fraction of patients—for example, 1 in 81 people taking a cholesterol drug for five years avoids a heart attack or death. This one-size-fits-all approach fails to account for individual genetic, environmental, and lifestyle factors that drive disease, leaving most patients without truly personalized prevention or intervention strategies.
Solution
PUER provides a comprehensive precision medicine platform that integrates genomics, proteomics, and metabolomics to map an individual's biology at the deepest molecular level. By analyzing the central dogma of biology—how DNA codes for proteins that, in concert with small molecules, determine traits and health outcomes—PUER identifies the 3-5 major health threats each person faces, such as heart disease, cancer, or neurodegenerative conditions. The platform reveals how inherited genetic factors interact with environment and lifestyle choices, allowing physicians to implement early detection and targeted interventions. PUER's technology was developed over 10 years with over $45M in research investment and has been validated in clinical trials, leading to discoveries of new blood tests and medications for cardiovascular disease. The company has collaborated with top 15 Big Pharma companies including Sanofi and Novartis, and formed a joint venture with Juvenescence to tackle aging and longevity.
Target Audience
Primary customers are physicians and healthcare professionals seeking precision medicine tools for early disease detection and personalized prevention, as well as individuals focused on optimizing their health, wellness, and longevity through deep biological insights.
Features
- Multi-omics integration combining whole-genome sequencing, proteomics, and metabolomics data to create a comprehensive molecular profile of each individual
- Proprietary AI and Big Data platform recognized as the deepest and most comprehensive in cardiovascular disease, capable of identifying novel causal biomarkers and disease subpopulations
- Discovery platform that has identified new blood tests for plaque detection in the heart and new causal biomarkers for atherosclerotic coronary artery disease
- Clinical validation through carefully designed trials (NCT01738828) with leading genomics, proteomics, and metabolomics companies
- Joint venture with Juvenescence focused on developing drugs to tackle aging and longevity, plus a G3 collaboration with Novartis addressing Lp(a)-driven cardiovascular disease
- B4X Therapeutics subsidiary applying the same platform to degenerative brain diseases, incubated at the Illumina Accelerator